JP2025084976A5 - - Google Patents
Info
- Publication number
- JP2025084976A5 JP2025084976A5 JP2025034492A JP2025034492A JP2025084976A5 JP 2025084976 A5 JP2025084976 A5 JP 2025084976A5 JP 2025034492 A JP2025034492 A JP 2025034492A JP 2025034492 A JP2025034492 A JP 2025034492A JP 2025084976 A5 JP2025084976 A5 JP 2025084976A5
- Authority
- JP
- Japan
- Prior art keywords
- initiation
- treatment
- monthly
- administrations
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627103P | 2018-02-06 | 2018-02-06 | |
| US62/627,103 | 2018-02-06 | ||
| US201862729333P | 2018-09-10 | 2018-09-10 | |
| US62/729,333 | 2018-09-10 | ||
| JP2022000341A JP7273204B2 (ja) | 2018-02-06 | 2022-01-05 | 眼科疾患の処置 |
| JP2023073187A JP7646727B2 (ja) | 2018-02-06 | 2023-04-27 | 眼科疾患の処置 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023073187A Division JP7646727B2 (ja) | 2018-02-06 | 2023-04-27 | 眼科疾患の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025084976A JP2025084976A (ja) | 2025-06-03 |
| JP2025084976A5 true JP2025084976A5 (https=) | 2026-01-08 |
| JP7852107B2 JP7852107B2 (ja) | 2026-04-27 |
Family
ID=65352014
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020536578A Active JP7005772B2 (ja) | 2018-02-06 | 2019-02-05 | 眼科疾患の処置 |
| JP2022000341A Active JP7273204B2 (ja) | 2018-02-06 | 2022-01-05 | 眼科疾患の処置 |
| JP2023073187A Active JP7646727B2 (ja) | 2018-02-06 | 2023-04-27 | 眼科疾患の処置 |
| JP2025034492A Active JP7852107B2 (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
| JP2025034493A Active JP7852108B2 (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020536578A Active JP7005772B2 (ja) | 2018-02-06 | 2019-02-05 | 眼科疾患の処置 |
| JP2022000341A Active JP7273204B2 (ja) | 2018-02-06 | 2022-01-05 | 眼科疾患の処置 |
| JP2023073187A Active JP7646727B2 (ja) | 2018-02-06 | 2023-04-27 | 眼科疾患の処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025034493A Active JP7852108B2 (ja) | 2018-02-06 | 2025-03-05 | 眼科疾患の処置 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210139576A1 (https=) |
| EP (1) | EP3749359A1 (https=) |
| JP (5) | JP7005772B2 (https=) |
| KR (3) | KR20250166355A (https=) |
| CN (4) | CN111699004A (https=) |
| AU (3) | AU2019219004B2 (https=) |
| CA (1) | CA3088355A1 (https=) |
| IL (1) | IL276383B2 (https=) |
| MX (1) | MX2020007527A (https=) |
| SG (1) | SG11202006712XA (https=) |
| TW (3) | TWI831764B (https=) |
| WO (1) | WO2019154776A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| KR20250057128A (ko) | 2015-12-30 | 2025-04-28 | 코디악 사이언시스 인코포레이티드 | 항체 및 이의 접합체 |
| AU2019212622B2 (en) | 2018-01-26 | 2024-05-23 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| EP3758737A4 (en) | 2018-03-02 | 2022-10-12 | Kodiak Sciences Inc. | IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF |
| MY195550A (en) | 2018-10-29 | 2023-01-31 | Hoffmann La Roche | Antibody Formulation |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| TWI785360B (zh) * | 2019-08-06 | 2022-12-01 | 美商建南德克公司 | 眼科疾病之個人化治療 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| TW202216761A (zh) | 2020-07-16 | 2022-05-01 | 瑞士商諾華公司 | 抗β細胞素抗體、其片段及多特異性結合分子 |
| EP4208201A1 (en) * | 2020-09-04 | 2023-07-12 | F. Hoffmann-La Roche AG | Antibody that binds to vegf-a and ang2 and methods of use |
| WO2022057888A1 (zh) * | 2020-09-17 | 2022-03-24 | 江苏恒瑞医药股份有限公司 | 特异性结合vegf和ang-2的双特异性抗原结合分子 |
| JP2024512701A (ja) * | 2021-03-30 | 2024-03-19 | アブプロ コーポレーション | 抗ａｎｇ２×ｖｅｇｆ多重特異性抗体を用いて脈絡膜新生血管形成を治療するための方法 |
| BR112023022439A2 (pt) | 2021-04-26 | 2023-12-26 | Celanese Eva Performance Polymers Llc | Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular |
| CN118139628A (zh) * | 2021-08-23 | 2024-06-04 | 阿维麦克思生物制药公司 | 用于转基因表达的组合物和方法 |
| CN117100845A (zh) * | 2022-10-24 | 2023-11-24 | 景泽生物医药(合肥)股份有限公司 | 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| ATE299938T1 (de) | 1997-05-02 | 2005-08-15 | Genentech Inc | Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen |
| AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
| PT1999154E (pt) | 2006-03-24 | 2013-01-24 | Merck Patent Gmbh | Domínios proteicos heterodiméricos modificados |
| JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー／エス | 二重特異性抗体の生産 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法 |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| ES2758994T3 (es) | 2010-11-05 | 2020-05-07 | Zymeworks Inc | Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc |
| KR20190049934A (ko) * | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| RS60499B1 (sr) | 2011-12-20 | 2020-08-31 | Medimmune Llc | Modifikovani polipeptidi za bispecifične skelete antitela |
| US9248181B2 (en) | 2012-04-20 | 2016-02-02 | Merus B.V. | Methods and means for the production of Ig-like molecules |
| SG11201408538PA (en) * | 2012-07-13 | 2015-02-27 | Roche Glycart Ag | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| CA2879597C (en) * | 2012-08-21 | 2021-01-12 | Opko Pharmaceuticals, Llc | Ophthalmic liposome formulations for treating posterior segment disease |
| WO2014177459A2 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| KR20150063728A (ko) | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-C/항 Ang2 이중 특이 항체 |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| CN114306575A (zh) * | 2014-12-11 | 2022-04-12 | 拜耳医药保健有限责任公司 | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 |
| AR103477A1 (es) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
| EP3454903A4 (en) | 2016-05-13 | 2020-08-19 | Askgene Pharma, Inc. | NEW DOUBLE ANTAGONISTS OF ANGIOPOIETIN 2, VEGF |
| EP4549463A3 (en) * | 2016-06-17 | 2025-07-30 | F. Hoffmann-La Roche AG | Purification of multispecific antibodies |
-
2019
- 2019-02-05 SG SG11202006712XA patent/SG11202006712XA/en unknown
- 2019-02-05 JP JP2020536578A patent/JP7005772B2/ja active Active
- 2019-02-05 KR KR1020257038946A patent/KR20250166355A/ko active Pending
- 2019-02-05 KR KR1020207025450A patent/KR20200119274A/ko not_active Ceased
- 2019-02-05 CN CN201980011416.4A patent/CN111699004A/zh not_active Withdrawn
- 2019-02-05 AU AU2019219004A patent/AU2019219004B2/en active Active
- 2019-02-05 CN CN202411925146.7A patent/CN119733046A/zh active Pending
- 2019-02-05 EP EP19703978.7A patent/EP3749359A1/en active Pending
- 2019-02-05 IL IL276383A patent/IL276383B2/en unknown
- 2019-02-05 CA CA3088355A patent/CA3088355A1/en active Pending
- 2019-02-05 KR KR1020247016479A patent/KR20240093772A/ko active Pending
- 2019-02-05 MX MX2020007527A patent/MX2020007527A/es unknown
- 2019-02-05 CN CN202510108289.7A patent/CN119909169A/zh active Pending
- 2019-02-05 CN CN202411926524.3A patent/CN119770646A/zh active Pending
- 2019-02-05 WO PCT/EP2019/052704 patent/WO2019154776A1/en not_active Ceased
- 2019-02-11 TW TW108104518A patent/TWI831764B/zh active
- 2019-02-11 TW TW113103154A patent/TWI885720B/zh active
- 2019-02-11 TW TW114116623A patent/TW202535932A/zh unknown
-
2020
- 2020-08-05 US US16/985,477 patent/US20210139576A1/en not_active Abandoned
-
2022
- 2022-01-05 JP JP2022000341A patent/JP7273204B2/ja active Active
-
2023
- 2023-02-09 US US18/166,996 patent/US20230416353A1/en active Pending
- 2023-04-27 JP JP2023073187A patent/JP7646727B2/ja active Active
-
2025
- 2025-03-05 JP JP2025034492A patent/JP7852107B2/ja active Active
- 2025-03-05 JP JP2025034493A patent/JP7852108B2/ja active Active
- 2025-08-22 AU AU2025220842A patent/AU2025220842A1/en active Pending
- 2025-08-22 AU AU2025220841A patent/AU2025220841A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025084976A5 (https=) | ||
| JP2025084977A5 (https=) | ||
| JP2023099094A5 (https=) | ||
| KR102412023B1 (ko) | 레날리도마이드 또는 포말리도마이드 및 ｃｄ38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도 | |
| AU2007238677B2 (en) | Use of IL-I antibodies for treating ophthalmic disorders | |
| CN109715189B (zh) | 靶向VE-PTP(HPTP-β)的人源化单克隆抗体 | |
| IL276383B2 (en) | Treatment of ophthalmologic diseases | |
| CN111787981B (zh) | 增加肌肉量和减少脂肪量的方法 | |
| JP2010502208A (ja) | 半減期の長い血清アルブミン結合タンパク質 | |
| CN114558129A (zh) | 用于降低心血管风险的方法 | |
| JP2024519629A5 (https=) | ||
| JP2025530139A (ja) | 抗ＦｃＲＮ抗体を用いた慢性炎症性脱髄性多発神経障害の治療方法 | |
| CN110913889A (zh) | 通过施用pcsk9抑制剂治疗糖尿病患者中的高脂血症的方法 | |
| JP2019521156A5 (https=) | ||
| JP7722991B2 (ja) | 抗ｆｃｒｎ抗体を用いた温熱自己免疫性溶血性貧血の治療方法 | |
| JP2021523881A5 (https=) | ||
| CN116710137A (zh) | 用于在治疗眼部疾病的方法中使用的vegf拮抗剂 | |
| EP3868396A1 (en) | Inhibitors and uses thereof | |
| JP7849919B2 (ja) | ヒトｄｒ３に特異的に結合する抗体及びその用途 | |
| WO2021018191A1 (zh) | Il-17拮抗剂治疗自身免疫疾病的方法 | |
| WO2018096467A1 (en) | Methods of treating acne using interleukin-17 (il-17) antagonists | |
| TW202608918A (zh) | 雙鏈構建體的配對 | |
| HK40121539A (zh) | 使用抗fcrn抗体治疗慢性炎性脱髓鞘性多发性神经病的方法 | |
| Dugel | Reframing the retina pipeline | |
| CN115812079A (zh) | 使用白细胞介素-17(il-17)拮抗剂治疗甲状腺眼病和格雷夫斯眼眶病的方法 |